Triptolide induces apoptosis of glioma cells by inhibiting NF-κB activation during oxidative stress Authors: Xinglan Li, Yubang Shan, Si Wang, Jia Wang, Xueyuan Heng Published: 2024 ABSTRACT AbstractGlioma is a common and fatal malignant primary brain tumor. Radiotherapy and first-line chemotherapy have little effect on the survival rate of patients, requiring alternative therapies. The main active ingredient of Tripterygium wilfordii Hook. F. triptolide (TP) has been shown to have anti-inflammatory and anti-proliferative properties, along with a wide range of anticancer activities. This study aimed to investigate the molecular mechanisms of triptolide in glioma treatment through network pharmacology and experimental validation. Cell viability was first assessed using Cell Counting Kit-8 (CCK8), followed by cell scratch assay and cell migration ability. Apoptosis-related markers, including TUNEL staining, Bcl-2-associated X protein (Bax), and B-cell lymphoma-2 (Bcl-2), were detected. Network pharmacology was used to predict the key targets of glioma, detect its signal pathways, screen the key components and targets for molecular docking, and explore the signaling pathways of TP. Lastly, immunofluorescence assays and ELISA were performed to elucidate the underlying mechanistic pathways. The network pharmacology data suggested that TP may inhibit glioma proliferation by regulating the signaling pathway of the nuclear factor kappa-B (NF-κB). The results showed that the underlying mechanism involved the regulation of the NF-κB signaling pathway to promote the generation of reactive oxygen species, thereby enhancing oxidative stress response and promoting cell apoptosis.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-024-80856-7.Keywords: Glioma, Triptolide, Oxidative stress, NF-κB pathwaySubject terms: Tumour immunology, Cell death, Mechanisms of disease Introduction Glioma is a tumor caused by the cancerous transformation of glial or precursor cells and is the most common form of brain tumor, accounting for 30–50% of primary brain tumors1,2. Gliomas are highly aggressive and rapidly proliferating intracranial malignant tumors, posing a significant treatment challenge3,4. The emergence of drug resistance and adverse effects in chemotherapy has posed additional hindrances in the treatment of glioma5. Therefore, finding effective drugs to treat malignant glioma has become a big challenge. Due to their low toxicity, multi-target, and multi-component properties, recent studies have highlighted the anti-tumor potential of traditional Chinese medicinal herbs. Triptolide (TP) is a traditional Chinese herb extracted from Tripterygium wilfordiiHook F6. , which has anti-inflammatory, antiangiogenic, immunosuppressive, and antitumorigenic properties7,8. There is increasing evidence that TP has potent broad-spectrum anticancer activity, effectively eradicating the majority of cancer cells originating in the prostate, colon, breast, kidney, and blood9–11. The antitumor mechanism of TP is mainly due to its specific inhibitory effect on nuclear factor kappa-B (NF-κB)12. Chen et al. discovered that activation of autophagy in colon cancer can inhibit the NF-κB signaling pathway, thereby downregulating the expression of inflammatory factors13. In addition to regulating cell proliferation, inflammation, and tissue remodeling, the NF-κB signaling pathway also regulates cellular activity. The complexity of cellular decision-making suggests that the multifaceted role of the NF-κB signaling pathway may be crucial for inter-pathway communication, enabling cells to adapt to stress, repair damage, and enhance tissue health. Inhibition of NF-κB due to overstimulation has been associated with the mitogen-activated protein kinases (MAPK) pathway during bidirectional gene regulation in living tissues; therefore, the inhibition of NF-κB activation can promote apoptosis14,15. In addition, TP can also be used for acute myeloid leukemia (AML) and colorectal cancer16,17. Oxidative stress is a prominent feature of tumor cells, persistent through the entire tumor development process, with significantly high levels of oxidative stress observed in patients with tumors. To adapt to the high levels of reactive oxygen species (ROS), tumor cells activate the antioxidant transcription factor activity during initiation and increase nicotinamide–adenine dinucleotide phosphate production during tumor progression and metastasis to adapt to oxidative stress18. Previous studies have reported that TP inhibits the proliferation of glioma cells in vitro and in vivo19. However, the comprehensive understanding of the biological effects of TP on glioma remains incomplete. Further studies are needed to determine the exact role of TP on oxidative stress in gliomas. Network pharmacology is a new method based on bioinformatics, systems biology, cheminformatics, and multipharmacology to filter and predict the crucial interactions between the chemical components of medicinal materials and disease targets20. In this study, network pharmacology and molecular docking were used to explore the cross-targets of TP and glioma and their related pathways, establish the interaction network, discover and verify its potential mechanisms, reveal the role of TP in vitro treatment of glioma, and develop a novel and effective treatment strategy for patients with gliomas. Materials and methods Materials TP (98%) was purchased from Yuanye Biotechnology Co., LTD (Shanghai, China). CCK8 kit (C6005) was obtained from New Cell & Molecular Biotech Co., LTD (Suzhou, China). ROS inhibitors CU-T12-9 (HY-110353) and N-acetylcysteine (NAC; HY-B0215) were acquired from MedChemExpress (Shanghai, China). Fetal bovine serum (10091148) and Dulbecco’s modified eagle medium (DMEM) (C11965500) were bought from Gibco (Shanghai, China). Reactive Oxygen Species Assay Kit (ROS) (S0033S), Colorimetric TUNEL Apoptosis Assay Kit (TUNEL) (C1086), Superoxide dismutase (SOD) (S0086), Lipid Peroxidation MDA Assay Kit (MDA) (S0131M), and GSH kits (S0073) were procured from Beyotime (Shanghai, China). Recombinant anti-Bax (Rabbit mAb) (GB154122), recombinant anti-Bcl-2 (Rabbit mAb) (GB154380), anti-IL-10 rabbit pAb (GB11108), and anti-TNF-alpha rabbit pAb (GB11188) antibodies were purchased from Servicebio (Wuhan, China). PrimeScript™ RT reagent kit with gDNA Eraser (Perfect Real Time) (RR047A) and TB Green®Premix Ex Taq™ II (Tli RNaseH Plus) (RR820A) were obtained from Takara (Beijing, China). Cell Culture U251 cells (CL-0237), mouse cardiac myocytes (MCM) (CP-M073), and LN229 cells (CL-0578) were purchased from Punosil (Wuhan, China). The cells were cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% double antibody, with the incubator maintained at 37 °C and 5% CO2. The degree of cell fusion was approximately 80% for passage and detection. Network pharmacological analysis The Isomeric SMILES information for ‘Triptolide’ was retrieved from PubChem (https://pubchem.ncbi.nlm.nih.gov/). This data was then entered into the SwissTargetPrediction (http://www.swisstargetprediction.ch/) to predict potential targets of TP. The obtained target names were verified using the UniProt (https://www.uniprot.org/). Next, ‘Neuroglioma’ was used as a keyword search for disease-related targets in GeneCards (https://www.genecards. org) and OMIM (http://www.omim.org). After compiling information on these relevant targets, we employed jvenn (http://www.bioinformatics.com.cn/static/others/jvenn/index.html) to create a Venn diagram and identify the intersection between the drug targets and disease targets. The common targets were imported into the Metascape (https://metascape.org/gp/index.html) for target gene analysis, with the species condition set as ‘Homo sapiens’ to acquire the GO function analysis and the enrichment of KEGG pathway analysis. Finally, these data were visualized using the Weishengxin online platform (https://www.bioinformatics.com.cn/) as bubble charts and bar graphs. Molecular docking verification The network topology parameters were analyzed using the built-in tool Network Analyzer in CytoScape 3.7.1, and the molecular docking between TP and four key target proteins of the NF-κB signaling pathway was verified based on their degree values. The PBD files of key target proteins were downloaded from the RCSB PDB (http://www.rcsb.org/) database set as “human”, and the 2D structure of core components was retrieved from the PubChem database. MOE2019.0102 was utilized for energy optimization of small molecules, elimination of water and small molecule ligands from protein receptors, and assessment of binding affinity and activity of key targets and core components based on the Docking Score. CCK8 determination CCK8 was used to detect the cytotoxicity of TP. U251, LN229, and MCM cells were inoculated into the 96-well plates and incubated for 24 h. Subsequently, the cells were treated with 0, 5, 10, 20, 40, 80, 160, and 320 nM of TP. After incubation, 100 µL of DMEM and 10 µL CCK8 solution were added to each well. The cells were then incubated for 30 min, and the absorbance of each well was detected at 450 nm. Immunofluorescence U251 and LN229 cells were treated with 40, 80, and 160 nM TP concentrations. The cells were inoculated and incubated overnight in a 24-well plate with a glass cover slide. Then, the cells were fixed with cooled 4% paraformaldehyde for 15 min, permeated with 1% Triton for 20 min, and closed with 10% goat serum for 30 min. The cells were then incubated with primary antibodies against BCL2-Associated X (Bax), B-cell lymphoma-2 (Bcl-2), p-nuclear factor kappa-B (p-NF-κB), c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase (p38-MAPK), tumor necrosis factor-α (TNF-α), and interleukin-10 (IL-10) at 4℃ for 24 h. Next, the cells were incubated with a fluorescent secondary antibody (1:1000) (Thermo, Shanghai, China) for 1 h. The nuclei were then stained with 4’,6-diamidino-2-phenylindole (DAPI) for 5 min, and fluorescence images were obtained by fluorescence scanning microscopy (MIDI:3Dhistech, Panoramic, Hungary) for analysis using Image J. ELISA Cytokines in the cell supernatant were measured using a commercial ELISA kit. SOD, MDA, and GSH were detected according to the manufacturer’s instructions. A 100 µL/well of cell supernatant and diluted standard were added and incubated at room temperature for 2 h. Finally, The ELISA plates were monitored at 450 nm using a microplate reader (BioTek, US). Real-time quantitative polymerase chain reaction (RT-qPCR) We extracted total RNA and determined its concentration and purity using a UV–VIS spectrophotometer. According to the PrimeScriptRT reagent Kit with gDNA Eraser (Perfect Real Time) kit, cDNA was reverse-transcribed. We then mixed primers, cDNA, and ROX Reference Dye or Dye II and performed RT-qPCR on the ABI Prism 7500HT (RT-PCR Amplification Apparatus) real-time fluorescent qPCR system. Finally, we calculated relative gene expression by the 2−ΔΔCT method. Cell scratch The U251 cells were inoculated in a 6-well plate. When about 80% of the bottom layer was covered, a straight line was drawn along the mark with a 10 µL tip, and TP was added to the culture plate. The scratch width was observed under the microscope at 0, 6, 12, and 24 h. TUNEL cell apoptosis detection A TUNEL assay kit was used according to the manufacturer’s instructions to detect and quantify the apoptotic response of U251 and LN229 cells. The cells were incubated with a TUNEL reaction mixture in a humidifying chamber at 37 °C for 1 h. After washing with PBS, the slides were observed using a fluorescence microscope. Detection of intracellular ROS U251 cells were incubated in a medium containing 2.5 µM dichlorodihydrofluorescein diacetate (DCFH-DA) for 30 min. The images were captured by fluorescence microscopy (Zeiss, Jena, Germany) and flow cytometry (Thermo Fisher Technologies, USA). Image J (NIH, Bethesda, MD, USA) was used to measure the ROS fluorescence intensity. Targeted inhibition of the NF-κB signaling pathway The NF-κB agonist, CU-T12-9, was dissolved in dimethyl sulfoxide (DMSO) according to the specifications provided. After cell attachment, 20 µM CU-T12-9 was added. The expression levels of Bax, Bcl-2, ROS, TNF-α, IL-10, IL-1β, and IL-6 were determined using Western blot. NAC was dissolved in DMSO according to the specifications provided. After cell attachment, 5 mM NAC was added. Bax, Bcl-2, and ROS expression levels were determined through immunofluorescence. Statistical analysis All data were statistically analyzed and visualized using GraphPad Prism 9.0. The data were expressed as mean ± SEM and were compared using a one-way analysis of variance (ANOVA) followed by a post hoc Tukey test. The statistical significance was set at *p < 0.05, **p < 0.01, ***p < 0.001, and NS > 0.05. Results TP played an anti-tumor role in vivo Before investigating the efficacy of TP, we determined its safety in U251, LN229, and MCM cells. CCK-8 assay was used to evaluate the effects of TP at different concentrations on 24-h glioma cell survival. As shown in Fig. 1A and S1A, TP inhibited U251 cell and LC229 cell proliferation, and the IC50 of the cell line was 80 nM after 24 h of treatment. Three doses of TP (40, 60, and 80 nM) were then selected for follow-up experiments. Figure S1B further illustrated that TP had no significant effect on the activity of MCM cells at concentrations ranging from 40 to 80 nM. The migration ability of tumor cells was crucial for tumor cell metastasis, and cell scratch experiments were performed to evaluate the migration effect at different concentrations of TP on U251 cells. In cell scratch experiments, different concentrations of TP inhibited the migration rate of tumor cells differently after 24 and 48 h (p < 0.01) (Fig. 1B). The apoptosis rate was significantly increased after treatment with TP (Fig. 1C and S1C). TP decreased Bcl-2 expression (Fig. 1D and S1D) and increased Bax expression (Fig. 1E and S1E). TP played an anti-tumor role in vivo. (A) Molecular structure formula of puerarin and cell viability of U251 cells after incubation with TP for 24 h was measured by CCK8. (B) Determination of U251 migration under different co-culture conditions. (C) The apoptosis level was evaluated by TUNEL assay and fluorescence quantitative analysis. (D) Bax in U251 cells were detected by immunofluorescence and quantitative analysis. (E) Bcl2 in U251 cells were detected by immunofluorescence and quantitative analysis. (**P < 0.01) (Scale bar, 20 μm) (n = 3). Network pharmacological analysis and molecular docking TP is a low molecular weight (360.4 Da) natural compound. Figure 1A shows the chemical structure of TP. To describe the mechanism of action of TP on glioma, we used a network pharmacological analysis to predict its potential targets. The keywords “Triptolide” and “Neuroglioma” identified 26 and 124 relevant targets from the RCSB PDB database, respectively. Eight targets were co-associated with the diseases and drugs (Fig. 2A). The biological processes involved in TP’s neurogliomal improvement mainly included response to oxygen levels, cellular response to external stimulus, and response to metal ion (Fig. 2C). The core signaling pathways were mainly lipid and atherosclerosis and NF-κB signaling pathways (Fig. 2B). The network diagram of TP–intersection target protein–signal transduction pathway was constructed by CytoScape3.7.1, and the transduction pathway is shown in Fig. 2D. The analysis of topological parameters ranked the closeness of the four target proteins in the NF-κB signaling pathway to TP in order of degree as follows: CD14, Bcl-2, PLAU, and PTGS2. Next, the four target proteins were molecule-docked with TP; the Docking Score values were all negative, indicating that the core components and key target proteins had good binding activity (Fig. 2E). Network pharmacological analysis and molecular docking. (A)Triptolide and Neuroglioma cross targets. (B) KEGG pathway enrichment analysis of 8 cross targets. (C) GO enrichment analysis of 8 cross targets. (D) Triptolide-Intersection target protein-Signal transduction pathway network diagram. The pink color represents Triptolide, the blue-purple color represents 8 Intersection target proteins, and the inverted triangle symbolizes the Signal transduction pathway. The font size of the nodes indicates their degree value, a larger font size signifies a higher degree value, indicating greater importance of the node in the network and its closer association with Triptolide. (E) Enhanced 3D and 2D visualizations of molecular docking interactions between TP and CD14, Bcl-2, PLAU, PTGS2. (F) p-NF-κB, JNK and p38-MAPK in U251 cells were detected by immunofluorescence. (G) Quantitative analysis of p-NF-κB, JNK and p38-MAPK expression levels. (**P < 0.01) (Scale bar: 20 μm) (n = 3). After the network pharmacological target screening, the NF-κB signaling pathway was selected for KEGG analysis. We evaluated the expression of p-NF-κB, JNK, and p38-MAPK using an immunofluorescence assay. As a member of the MAPK pathway, JNK is involved in many downstream cascades of the ROS signal transduction pathways and can act as pro-apoptotic kinases, playing a pivotal role in both extrinsic and intrinsic apoptotic pathways21,22. Compared to the control group, the expression of p-NF-κB was significantly reduced, and JNK and p38-MAPK expressions were significantly increased in the TP-treatment group (Fig. 2F, G and S2A–G). Activation of oxidative stress by TP in U251 and LN229 cells The NF-κB signaling pathway plays a vital role in inflammation, immunity, and regulating ROS in cells23. To determine the protective effect of TP on glioma-mediated oxidative damage, we evaluated a range of oxidative and antioxidant markers. Compared to the control group, TP increased mitochondrial ROS levels in a concentration-dependent manner (p < 0.05) (Fig. 3A). In addition, MDA was significantly increased in the TP-treatment group compared to the control group (p < 0.01) (Fig. 3D). Moreover, SOD and GSH levels in the TP-treatment group were significantly decreased (p < 0.01) (Fig. 3B, C). During oxidative stress, cytokines recruit and activate more inflammatory cells. The TP-treatment group exhibited a significant increase in pro-inflammatory factor TNF-α expression compared to the control group (Fig. 3E, F, and S3A–C). Conversely, the anti-inflammatory factor IL-10 showed a substantial decrease in expression, with the pro-inflammatory effect being more pronounced in the high-dose TP-treatment group (p < 0.01) (Fig. 3E, F, and S3A–C). RT-qPCR demonstrated that the mRNA expression of IL-1β and IL-6 increased significantly, proving that TP can activate oxidative stress and promote inflammatory cell infiltration (Fig. 3G). TP activates oxidative stress in U251 cells. (A) The fluorescence of ROS was quantified using fluorescent microplates and quantitative analysis. (B-D) The contents of SOD, MDA and GSH in cell lysates were detected by enzyme-labeled instruments of commercial kits. Data are presented as mean ± standard deviation (SD). (E) TNF-α and IL-10 in U251 cells were detected by immunofluorescence. (F) Quantitative analysis of TNF-α and IL-10 expression levels. (G) The expression of IL-1β and IL-6 were quantitatively detected by qPCR. (**P < 0.01) (Scale bar, 20 μm) (n = 3). Activation of NF-κB pathway verified the pro-apoptotic effect of TP on U251 and LN229 cells To further determine the NF-κB signaling pathway effect on the remission of glioma by TP, we treated U251 and LN229 cells with CU-T12-9. CU-T12-9 is a specific TLR1/2 agonist that can activate the NF-κB signaling pathway, increase pro-inflammatory factors downstream of the NF-κB signaling pathway, and improve the autoimmune response. Cell scratch experiments showed that the addition of CU-T12-9 promoted the migration rate of tumor cells after 24 and 48 h (p < 0.01), but the co-treatment of TP and activator reversed cell migration (Fig. 4A). Following the activator addition, there was a significant decrease in apoptosis rate (Fig. 4B, C), a notable reduction in Bax expression, and a significant increase in Bcl-2 expression (Fig. 4D–G and S4A, B). The combination of drug and activator addition promoted apoptosis. These results suggested that TP may promote apoptosis by inhibiting NF-κB activity. Activation of NF-κB pathway verified the pro-apoptotic effect of TP on U251 cells. (A) Determination of U251 migration under different co-culture conditions. (B) The apoptosis level was evaluated by TUNEL assay after CU-T12-9 treatment. (C) Quantitative analysis of TUNEL staining. (D) Quantitative analysis of Bax expression levels. (E) Quantitative analysis of Bcl-2 expression levels. (F) Bax in U251 cells were detected by immunofluorescence after CU-T12-9 treatment. (G) Bcl-2 in U251 cells were detected by immunofluorescence after CU-T12-9 treatment. (**P < 0.01) (Scale bar, 20 μm) (n = 3). Activation of the NF-κB pathway verified the oxidative stress-promoting effect of TP on U251 and LN229 cells The NF-κB signaling pathway can regulate oxidative stress, so we used NF-κB agonists to test whether NF-κB regulates ROS. Compared to the control group, CU-T12-9 significantly inhibited the increase of ROS (p < 0.01) (Fig. 5A). Moreover, MDA content in the CU-T12-9 group was significantly increased compared to the TP-treatment group (p < 0.01) (Fig. 5B). SOD and GSH levels were significantly decreased (p < 0.01) (Fig. 5C, D). The expression of TNF-α was also significantly decreased after the addition of the activator, while the expression of IL-10 was substantially increased (Fig. 5E, F, and S5A–C). RT-qPCR results showed that the mRNA expression of IL-1β and IL-6 decreased significantly after CU-T12-9 addition (Fig. 5G). Activation of the NF-κB pathway verified the oxidative stress-promoting effect of TP on U251 cells. (A) The fluorescence of ROS was quantified using fluorescent microplates after CU-T12-9 treatment and quantitative analysis. (B-D) The contents of MDA, SOD and GSH in cell lysates were detected by enzyme-labeled instruments of commercial kits. Data are presented as mean ± standard deviation (SD). (E) TNF-α and IL-10 in U251 cells were detected by immunofluorescence after CU-T12-9 treatment. (F) Quantitative analysis of TNF-α and IL-10 expression levels. (G) The expression of IL-1β and IL-6 after CU-T12-9 treatment was quantitatively detected by qPCR. (**P < 0.01) (Scale bar, 20 μm) (n = 3). ROS production and inhibition of NF-κB signaling pathway played an essential role in TP-induced apoptosis Intracellular ROS plays a crucial role in cell survival24. NAC is commonly used to reduce ROS production25. We used ROS inhibitors to investigate whether ROS production is involved in TP-induced apoptosis. The inhibitor effectively reduced the generation of ROS, demonstrating NAC effectiveness (Fig. 6A). Compared to the control group, pretreatment of U251 cells with NAC significantly increased cell migration (Fig. 6B) and cell survival (Fig. 6C, D). NAC addition significantly decreased Bax expression and enhanced Bcl-2 expression. The co-addition of drugs significantly enhanced apoptosis and reversed the expressions of Bax and Bcl-2 in U251 and LN229 cells (Fig. 6E, F, and S6 A-C). ROS production and inhibition of NF-κB signaling pathway plays an essential role in TP-induced apoptosis. (A) The fluorescence of ROS was quantified using fluorescent microplates after NAC treatment and quantitative analysis. (B) Determination of U251 migration under different co-culture conditions. (C) The apoptosis level was evaluated by TUNEL assay after NAC treatment. (D) Quantitative analysis of TUNEL staining. (E) Bax and Bcl-2 in U251 cells were detected by immunofluorescence after NAC treatment. (F) Quantitative analysis of Bax and Bcl-2 expression levels. (**P < 0.01) (Scale bar, 20 μm) (n = 3). Discussion In recent years, there has been a growing interest in traditional Chinese medicine for cancer treatment. Gliomas are highly malignant tumors of the central nervous system characterized by their aggressive and uncontrolled growth, leading to a poor overall prognosis and low long-term survival rates26. Studies have found that TP has multiple pharmacological effects12,27. Although many studies have shown the efficacy of TP in many tumor types, the specific aspects and potential anti-gliomal mechanisms have not been effectively explored. Apoptosis is a highly regulated programmed death, which is activated to eliminate dysfunctional cells. Drug-induced apoptosis is an essential mechanism in the chemotherapy of cancers28. Previous studies have shown that TP can inhibit malignant glioma proliferation19. To verify the effect of TP on glioma cells, the effect on apoptosis was first analyzed using a cell scratch test, TUNEL staining, and apoptotic marker staining. The study found that TP inhibited glioma cell migration and promoted glioma cell apoptosis. In addition, we used network pharmacology and molecular docking to investigate the signaling pathways that TP and glioma key targets enriched. Network pharmacological analysis revealed eight cross-targets for glioma treatment, and KEGG enrichment analysis showed that these targets were involved in the NF-κB and lipid and atherosclerosis signaling pathways. Hence, we focused on the NF-κB signaling pathway. To better understand the relationship between TP and glioma targets, we simulated the molecular effects of TP on glioma through molecular docking to verify the results of network pharmacological analyses. Molecular docking techniques can accurately predict the target proteins binding to small molecular ligands, demonstrating potential drug effects against gliomas. Lower binding energies between the ligands and macromolecules generally result in a more stable conformation and a higher probability of interaction. In addition, conformations with negative binding energies are more likely to spontaneously bind to each other. The docking results indicated that the active component of TP can form a relatively stable binding conformation with glioma-associated targets, suggesting that TP may exert its effects on gliomas by interacting with proteins associated with CD14, Bcl-2, PLAU, and PTGS2. NF-κB activation plays an anti-apoptotic role during cell death; NF-κB translocation to the nucleus and binding to DNA are the key steps29,30. It was found that TPL and CUR inhibit FLS proliferation, increase apoptosis, and regulate IL-17/NF-κB signaling, thereby reducing inflammatory cell infiltration and invasive growth of FLS31. The NF-κB signaling pathway is important in cell signaling and plays a key role in regulating various physiological processes, such as immune and inflammatory responses, cell growth, and cell death32. ROS production is toxic to cells at certain levels, causing oxidative stress by reacting with proteins, lipids, and nucleic acids33. Overproduction of ROS can trigger apoptosis and cell death34. This study demonstrated that the use of ROS inhibitors effectively disrupted the activity of U251 and LN229 cells, resulting in the inhibition of ROS production and promotion of cell survival. Recent studies have shown that NF-κB is closely related to apoptosis, involved in the transcriptional regulation of many apoptosis-related genes, and has a bidirectional effect of inhibiting and promoting apoptosis35. In most cases, NF-κB activation generally promotes cell survival36. The JNK signaling pathway is a crucial pathway that interacts with NF-κB, inhibiting prolonged JNK activation and consequently reducing cell death via apoptosis37,38. JNK and p38/MAPK signaling pathways, as classic MAPK signaling pathways, are involved in cell inflammation, apoptosis, and cell growth. Thus, our study used immunofluorescence to detect the expression of JNK, p38-MAPK, and p-NF-κB protein. TP was found to promote apoptosis and inhibit NF-κB activity in a concentration-dependent manner. In addition, this study also confirmed that TP can promote ROS generation, enhance oxidative stress, and promote the recruitment of inflammatory cytokines. Therefore, TP may promote apoptosis by affecting NF-κB activity and ROS levels. To further verify the role of NF-κB in promoting apoptosis of glioma cells, we used NF-κB agonist to activate the NF-κB pathway and observe apoptosis and oxidative stress regulation. It was found that NF-κB agonists can promote gliomal cell survival, inhibit ROS activity, and increase anti-inflammatory factors’ production. Compared with NF-κB agonists alone, the combination of drugs and agonists reversed this phenomenon. In summary, our findings indicated that oxidative stress and apoptosis played crucial roles in the therapeutic effects of TP on glioma. TP can inhibit NF-κB activity, induce gliomal apoptosis, and enhance the cellular response during oxidative stress. However, the specific molecular targets of ROS involved in the NF-κB signaling pathway have not been fully understood, which could be crucial for determining the exact molecular mechanism. Secondly, in this manuscript, we only conducted in vitro verification, and did not explore the mechanism and efficacy in vivo. In addition, the specific mechanism of protein interaction needs to be further studied. These inadequacies are what we will address next. Conclusion In conclusion, our results suggested that treatment with TP can effectively promote the apoptosis of U251 cells and LN229 cells by inhibiting NF-κB activity and promoting ROS. These findings indicated that TP-induced oxidative stress may be a possible mechanism for the effects of TP in glioma cells. However, additional investigation was required to uncover more accurate molecular mechanisms. This was crucial for advancing our understanding of the anti-tumor properties of TP in gliomal cells. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Author contributions X.L.: Writing – original draft, Project administration, Methodology, Data curation, Conceptualization. Y.S.: Methodology, Formal analysis, Software, Data curation. S.W.: Validation, Formal analysis, Data curation. J.W.: Methodology, Formal analysis, Data curation. X.H.: Writing – review & editing, Supervision, Resources, Conceptualization. All authors reviewed the manuscript. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Data availability All data generated or analysed during this study are included in this published article [and its supplementary information files]. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Xinglan Li and Yubang Shan contributed equally to this work. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement All data generated or analysed during this study are included in this published article [and its supplementary information files].